TC
ARNA

TFS Capital’s Arena Pharmaceuticals Inc ARNA Stock Holding History

TFS Capital’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-34,009
Closed -$497K – 826
2017
Q1 		$497K Buy
34,009
+25,818
+315% +$382K 0.16% 184
2016
Q4 		$116K Sell
8,191
-52,802
-87% -$818K 0.03% 620
2016
Q3 		$1.07M Buy
60,993
+38,719
+174% +$642K 0.26% 146
2016
Q2 		$381K Buy
22,274
+19,510
+706% +$349K 0.07% 469
2016
Q1 		$54K Buy
+2,764
New +$44.3K 0.01% 944
2015
Q4 		– Sell
-2,195
Closed -$42K – 973
2015
Q3 		$42K Buy
+2,195
New +$74.5K ﹤0.01% 853
2015
Q1 		– Sell
-16,168
Closed -$561K – 1182
2014
Q4 		$561K Buy
+16,168
New +$656K 0.05% 550

Other funds holding ARNA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

TFS Capital's ARNA Position: Q2 2017 in Review

TFS Capital sold out of Arena Pharmaceuticals Inc (ARNA) in Q2 2017, closing a stake of 34,009 shares — an estimated $497K sold.

TFS Capital first reported a position in ARNA in Q4 2014 and held it in 7 quarters. The position peaked at $1.07M in Q3 2016. 102 funds tracked by Wall St. Rank hold ARNA as of Q2 2017.

  • TFS Capital reported no remaining Arena Pharmaceuticals Inc position as of Q2 2017 after selling out during the quarter.
  • TFS Capital sold 34,009 Arena Pharmaceuticals Inc shares in Q2 2017, an estimated $497K.
  • TFS Capital first reported a position in Arena Pharmaceuticals Inc in Q4 2014 and held it in 7 quarters.
  • TFS Capital's Arena Pharmaceuticals Inc position peaked at $1.07M in Q3 2016.
  • 102 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q2 2017.

Based on TFS Capital's 13F filing for Q2 2017, filed 11 Aug 2017.